News
ZNTL
--
0.00%
--
Insider Sell: Zentalis Pharmaceuticals
MT Newswires · 01/21 06:19
Zentalis Pharmaceuticals Inc (ZNTL) COO Kevin D. Bunker Sold $792,400 of Shares
COO of Zentalis Pharmaceuticals Inc (30-Year Financial, Insider Trades) Kevin D. Bunker (insider trades) sold 10,000 shares of ZNTL on 12/20/2021 at an average price of $79.24 a share.
GuruFocus.com · 12/22/2021 15:15
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Simply Wall St. · 12/21/2021 17:03
SVB Leerink Maintains Outperform on Zentalis Pharmaceuticals, Raises Price Target to $97
SVB Leerink analyst Andrew Berens maintains Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform and raises the price target from $89 to $97.
Benzinga · 12/17/2021 09:41
Zentalis Pharmaceuticals Inc (ZNTL) COO Kevin D. Bunker Sold $717,100 of Shares
COO of Zentalis Pharmaceuticals Inc (30-Year Financial, Insider Trades) Kevin D. Bunker (insider trades) sold 10,000 shares of ZNTL on 12/10/2021 at an average price of $71.71 a share.
GuruFocus.com · 12/14/2021 16:15
SVB Leerink Maintains Outperform on Zentalis Pharmaceuticals, Raises Price Target to $89
SVB Leerink analyst Andrew Berens maintains Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform and raises the price target from $84 to $89.
Benzinga · 12/10/2021 11:10
Zentalis Pharmaceuticals Inc (ZNTL) President & CEO Anthony Y Sun Sold $1.6 million of Shares
GuruFocus News · 12/03/2021 11:01
Zentalis Pharmaceuticals Inc (ZNTL) COO Kevin D. Bunker Sold $759,900 of Shares
GuruFocus News · 11/24/2021 13:15
Zentalis Pharmaceuticals Insider Sold Over $750K In Company Stock
Cam Gallagher, Insider at Zentalis Pharmaceuticals (NASDAQ:ZNTL), made a large insider sell on November 15, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Gallagher sold ...
Benzinga · 11/17/2021 16:35
BRIEF-Zentalis Pharmaceuticals Announces U.S. FDA Fast Track Designation Uterine Serous Carcinoma Treatment
reuters.com · 11/17/2021 12:19
FDA grants Fast Track tag for Zentalis Pharma's ZN-c3 in uterine serous carcinoma
Zentalis Pharmaceuticals (NASDAQ:ZNTL) announces that the FDA has granted Fast Track designation to ZN-c3, an oral WEE1 inhibitor product candidate, for the treatment of recurrent or persistent uterine serous carcinoma
Seekingalpha · 11/17/2021 12:18
Zentalis Pharmaceuticals Announces Fast Track Designation Granted by the U.S. FDA to ZN-c3 for the Treatment of Uterine Serous Carcinoma
Potentially registrational Phase 2 trial of ZN-c3 in USC is underway, with initial enrollment and safety update expected in 2H 2022NEW YORK and SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage bio...
GlobeNewswire · 11/17/2021 12:00
HC Wainwright & Co. Maintains Buy on Zentalis Pharmaceuticals, Raises Price Target to $120
HC Wainwright & Co. analyst Andrew Fein maintains Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Buy and raises the price target from $80 to $120.
Benzinga · 11/11/2021 11:17
--HC Wainwright Adjusts Price Target on Zentalis Pharmaceuticals to $120 From $80, Reiterates Buy Rating
MT Newswires · 11/11/2021 06:55
Zentalis Pharmaceuticals EPS beats by $1.22
Zentalis Pharmaceuticals (NASDAQ:ZNTL): Q3 GAAP EPS of -$0.09 beats by $1.22. Cash, cash equivalents and marketable securities of of $366.8M Press Release
Seekingalpha · 11/10/2021 13:56
Zentalis Pharmaceuticals' Q3 Loss Narrows, Operating Expenses Rise
MT Newswires · 11/10/2021 08:20
-- Earnings Flash (ZNTL) ZENTALIS PHARMACEUTICALS Reports Q3 Loss $-0.09
MT Newswires · 11/10/2021 07:10
Zentalis Pharmaceuticals to Present at Two Upcoming Investor Conferences
NEW YORK and SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways ...
GlobeNewswire · 11/09/2021 12:00
Director Of Zentalis Pharmaceuticals Makes $830K Sale
Cam Gallagher, Director at Zentalis Pharmaceuticals (NASDAQ:ZNTL), made a large insider sell on November 5, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that Gallagher sold ...
Benzinga · 11/08/2021 15:07
Zentalis Pharmaceuticals Insider Trades $1.7M In Company Stock
Anthony Y Sun, President And CEO at Zentalis Pharmaceuticals (NASDAQ:ZNTL), made a large insider sell on November 2, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Sun s...
Benzinga · 11/03/2021 15:26
Webull provides a variety of real-time ZNTL stock news. You can receive the latest news about Zentalis Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ZNTL
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidates, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors. Its other products include ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of non-Hodgkin’s lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.